Photo - MedVector Clinical Trials
play_arrow
View
49922

MedVector Clinical Trials

We connect subjects to clinical studies using telemedicine.

USA, California
Market: Medicine, Telecommunications, Pharmacology, Another
Stage of the project: Prototype or product is ready

Date of last change: 19.10.2020
Rating
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:

Idea

MedVector’s mission is to greatly accelerate the clinical trial process allowing Pharma to save lives, faster. Our proprietary telemedicine platform increases patient access by removing geographic barriers, increases doctor participation by not referring-away, and balances demographics for the FDA. Now everyone has access to advanced medicine regardless of location or economic status.

Current Status

Pre revenue about to launch.

Market

In 2017, 4 million subjects were needed for clinical trials, but only 1.8 million were enrolled, leaving a missing 2.2 million untapped (source). Our accessible technology and reach can address this crucial valley.

Our goal is to fill the 2.2 million subject gap worth $57.4 billion by expanding the supply side of the market to meet the demand. While MedVector is expanding the market rather than competing for current market share, if successful, it will inevitably capture some of the current market as well.

Problem or Opportunity

Before Pharmaceutical companies can sell or market new drugs to the public, they must conduct a Clinical Trial to get the approval of the FDA. Clinical trials are notoriously slow due to HIPAA privacy laws, making finding, recruiting, and enrolling patients into clinical studies very difficult. The #1 delay in clinical trials is patient recruitment. While a single patient might only take 6-12 months to complete a study, the average length of a clinical trial is more than 10 years! (source) And the problem is bigger than just finding the patients. Our research concludes the majority of qualified subjects are unattainable due to geography, HIPAA privacy laws, socioeconomic limitations, or doctors and gatekeepers unwilling to refer-away.

To make the problem worse, the 20 year clock on the medical patent starts with the first subject in a clinical trial. So, for every day/month/year lost in the clinical trial, is also a day/month/year lost patent protection (profitability) for Pharma. And these numbers are really big… For a medication like Humira, this equates to $1.66 BILLION a month.

Solution (product or service)

At MedVector, we believe greater patient access through telemedicine is the key to faster clinical trials. Our industry-first telemedicine platform for finding, enrolling, and connecting subjects to clinical studies is the solution. With MedVector’s Prime-Control Telemedicine Technology, no subject is too far away or left behind.

Competitors

While there are lots of new businesses in the space, we're created a unique mousetrap that allows us to partner with most of our "competitors." Our biggest direct competition risk is "the old way," similarly to how Uber's biggest competitor was "hailing a taxi."

There are also other companies using telemedicine for clinical trials, but for different reasons. For example, Science37 is using telemedicine to alieviate dropout rates, whereas we are using it to eliminate geographic constraints.

Advantages or differentiators

MedVector has developed the first "Prime-Control Telemedicine," which is the opposite of peer-to-peer. So, while most telemedicine requires downloads, settings, passwords, ours knows where it is and it just works.

Also, MedVector has created one of the largest searchable hospital networks while remaining HIPAA compliant. Hospitals and Private Practices are willing to share data with us because our technology protects them from referring away.

Finance

MedVector has a 35% markup on medical testing done at subject locations. At maturity we have other revenue streams we can turn on, such as patient sourcing fees and profit sharing agreements with hospitals and private practices.

Business model

MedVector connects patients to studies using HIPAA-compliant video conferencing technology called Telemedicine. This increased access allows for more diverse subject groups, easier FDA approval, and in turn, more affordable medications.

Our remote clinical service eliminates geographic barriers because our plug-and-play telemedicine kit can be drop-shipped to any hospital, private practice, or surgery center. And, for appointments with no medical tests, we’re working on an Ap for at-home use. Now, anyone can participate in advanced medicine regardless of where they live or economic status.

Once subject-candidates have been identified, MedVector connects them to approved clinical trial sites, via telemedicine, from the comfort and convenience of their home hospital or doctor’s office. Because these subjects use their local facilities to complete clinical trials, there are no more horrible commutes, and all of the medical tests associated with the study become billable revenue for the local hospital/practice.

Money will be spent on

Our current raise is to finance our launch team.

Team or Management

Risks

Odd section... There are abundant standard risk of any startup. However, we do not need FDA approval nor are we waiting for regulatory changes.

Incubation/Acceleration programs accomplishment

Incubator - Scale LA (Los Angeles)
Accelerator - NewChip (Austin)

Won the competition and other awards

Top 100 of Pepperdine's Most Fundable Companies (2020)
Finalist RESI Pitch Competition (JPM SF 2019)

Product Video

5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility17
star0
Add to favorites
Delete from favorites
share
close
thumb_up0
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video